Eagle Asset Management Inc. reduced its holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 1.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 986,783 shares of the biotechnology company’s stock after selling 19,439 shares during the quarter. Eagle Asset Management Inc. owned about 1.53% of Sarepta Therapeutics worth $55,228,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Hall Laurie J Trustee increased its holdings in Sarepta Therapeutics by 2,430.8% in the fourth quarter. Hall Laurie J Trustee now owns 3,290 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 3,160 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Sarepta Therapeutics by 39.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 977 shares in the last quarter. Aperio Group LLC bought a new stake in Sarepta Therapeutics in the fourth quarter worth approximately $219,000. Legato Capital Management LLC bought a new stake in Sarepta Therapeutics in the fourth quarter worth approximately $234,000. Finally, US Bancorp DE increased its holdings in Sarepta Therapeutics by 35.0% in the fourth quarter. US Bancorp DE now owns 4,224 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 1,095 shares in the last quarter. Institutional investors and hedge funds own 82.41% of the company’s stock.
In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the sale, the director now owns 13,333 shares in the company, valued at $745,181.37. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 9.60% of the company’s stock.
SRPT has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on Sarepta Therapeutics in a report on Friday, December 1st. They issued a “buy” rating and a $75.00 target price for the company. Zacks Investment Research upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a report on Monday, October 30th. Needham & Company LLC reiterated a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, October 27th. Oppenheimer reiterated a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. Finally, BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, December 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have issued a buy rating to the stock. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus target price of $64.65.
Shares of Sarepta Therapeutics Inc (SRPT) opened at $64.00 on Friday. The company has a market capitalization of $4,140.00, a P/E ratio of -31.37 and a beta of 1.49. Sarepta Therapeutics Inc has a 1-year low of $26.96 and a 1-year high of $68.90. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04.
ILLEGAL ACTIVITY NOTICE: This story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://ledgergazette.com/2018/02/17/sarepta-therapeutics-inc-srpt-position-lowered-by-eagle-asset-management-inc.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.